Investor Presentaiton slide image

Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T Compelling CART data in lupus supports expanding new modality to address unmet need Potential transformational efficacy and favorable safety demonstrated with CD19 CAR T Disease Remission Post CART Treatment¹ SLEDAI Data Suggests Immune System Reset² Before CAR T After CAR T Before CAR T After CAR T 20 100% 20 100% 15 80% 15 All patients achieved complete remission 60% 10 10 5 5 40% Remission 20% 0 0 0 0 0 0 0 ■Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6 Pt. 7 80% 60% 40% 20% 0% 0% Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 ■Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6 Pt. 7 7/7 pts achieved durable DORIS complete remission off all therapy; encouraging safety & tolerability with only grade 1 cytokine release syndrome and no neurotoxicity Patient immune system reset after CAR T treatment: Measurement of immunoglobulins shift from mature B-cells expressing IgA & IgG to naïve B-cells expressing IgM & IgD IgD ■IgM IgA IgG Ill Bristol Myers Squibb™ 1. Adapted from Taubmann, J., et al EULAR (2023): 93-94. 2. Adapted from Mackensen, A., Müller, F., Mougiakakos, D. et al. Nat Med 28, 2124-2132 (2022) Not for Product Promotional Use 68
View entire presentation